A mitochondrial signal, not a stimulant.
A compounded mitochondrial-derived signaling peptide studied in cellular stress-response and AMPK-related metabolic biology.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
About 10 minutes. No charge unless your clinician approves.
A signal written in mitochondrial DNA.
Mitochondria are usually treated like batteries. MOTS-c is a reminder that they also communicate. The peptide is encoded in mitochondrial DNA rather than the nuclear genome, which puts it inside one of the more unusual signaling systems in human biology.
That unusual origin is the reason to pay attention.
Under metabolic stress, research in human cells and experimental models shows endogenous MOTS-c can move into the nucleus and participate in AMPK-dependent stress-response signaling.1 Human studies have also measured changes in circulating endogenous MOTS-c during metabolic challenges and exercise.23 Those findings place the body’s own MOTS-c at a documented intersection of mitochondrial signaling, cellular stress, and metabolism.
The distinction matters: those human findings describe endogenous MOTS-c, not a guaranteed treatment effect from an injected compounded peptide. But they give the molecule a precise biological story that is much more interesting than another promise to “boost metabolism.”
MOTS-c is a signal, not a stimulant. It does not replace exercise or serve as a weight-loss shortcut. Your clinician evaluates the AMPK and mitochondrial-signaling biology inside your actual metabolic plan.
- Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to… Cell Metab. 2018.PubMed
- Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in… Clin Endocrinol (Oxf). 2019.PubMed
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of… Nat Commun. 2021.PubMed
For people who already know effort is not the whole metabolic story.
The Markers Moved Before the Habits Did
Training and nutrition are still part of your life, but the numbers are drifting anyway. You want the biology underneath those markers evaluated before the answer becomes simply “try harder.”
The GLP-1 Conversation Is Only One Part
You are using, considering, or coming off a GLP-1 and want the rest of the metabolic system in view too. Appetite is one lever. Mitochondrial signaling is a different biological question.
The Exercise Reader
You train consistently and you have seen MOTS-c described as an “exercise mimetic.” You want the version of the conversation that distinguishes what the body does during exercise from what an injected treatment has actually been shown to do.
MOTS-c was nominated through FDA’s 503A process for obesity and received a favorable 7-5-2 PCAC recommendation in July 2026. The recommendation is advisory, FDA has not acted, and MOTS-c is not currently on the 503A Bulks List or in Category 1 enforcement discretion. The obesity nomination does not establish a weight-loss effect. The preparation offered here is compounded and is not an FDA-approved drug product.
This might not be the right fit if:
- You have a history of significant hypoglycemia that has not been evaluated.
- You use insulin or other glucose-lowering medication without provider clearance.
- You are pregnant or breastfeeding.
- You have a known hypersensitivity to any component of the preparation.
- You are under 18.
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
MOTS-c, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- An independent licensed provider reviews your full Assessment and gives you a real answer either way.
- Glucose history, medications, and the rest of your metabolic plan are reviewed before treatment is prescribed.
- If approved, your dose and duration are set for you, with follow-up built into your care.
- Provider review, the prescription if approved, pharmacy, and shipping handled inside one plan.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Longevity.
BPC-157
The peptide everyone asks about, inside real medicine.
Compounded BPC-157 sourced through a licensed US pharmacy and placed inside clinician review, not a research-vendor checkout.
Epithalon
The longevity peptide that rewards skepticism.
A compounded Epithalon prescription for the well-read patient who wants the molecule, evidence gaps, and sourcing stated plainly.
Glutathione
Antioxidant defense, under clinical direction.
Compounded injectable glutathione for clinician-guided antioxidant defense beyond the supplement aisle.
Serious risks
- Diabetes medications and a history of hypoglycemia deserve specific review
- Other treatments that affect blood sugar deserve review, even though a defined drug interaction has not been established
- Pregnancy and breastfeeding safety are not established
- The long-term effects of repeated exogenous MOTS-c exposure are uncertain
- Human safety data for administered MOTS-c are limited, and there is no controlled safety database for the compounded use offered here
Commonly reported
- Injection-site reactions are possible with an injected preparation
MOTS-c is studied in AMPK, glucose, and insulin-related signaling. Your provider reviews glucose history, medications, relevant metabolic disease, and other risk factors before deciding whether treatment belongs in your plan.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
No. MOTS-c is studied as a mitochondrial-derived signaling peptide, not as a stimulant. Research connecting the body's own MOTS-c to exercise does not establish that injected MOTS-c recreates exercise, replaces training, or produces a stimulant-like effect.
MOTS-c was nominated through FDA’s 503A process for obesity and received a favorable recommendation from the Pharmacy Compounding Advisory Committee in July 2026. That is a regulatory review step, not an FDA approval, and FDA has not issued a final rule adding MOTS-c to the 503A Bulks List. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
AnthologyRX+ does not present it that way. Weight and glucose effects reported in animal models do not establish a weight-loss result in people, and the FDA nomination for obesity is a regulatory fact rather than proof of efficacy. If weight loss is your primary goal, your provider can evaluate treatments with direct human evidence for that outcome instead.
That is a provider decision because controlled interaction data are limited. Your Assessment should include GLP-1 drugs, metformin, insulin, sulfonylureas, and any other medication that affects glucose or appetite. MOTS-c is being studied around metabolic signaling, so adding it to an existing plan without reviewing the whole plan would miss the point of clinician-guided care.
MOTS-c is a perfect example of why an interesting mechanism is not enough. Here, a licensed provider reviews whether the peptide belongs in your metabolic plan and a licensed US pharmacy compounds it to an individual prescription. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. AnthologyRX+ gives you a place to explore unusual biology without pretending unusual automatically means proven.
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, and FDA Warning Letter to Gram Peptides, March 31, 2026.